Epithalon: a longevity peptide with big claims and thin human data

How Epithalon (Epitalon) works

Epithalon is a synthetic tetrapeptide (alanine, glutamic acid, aspartic acid, glycine) based on the composition of epithalamin, an extract of animal pineal glands. In cell and animal studies it has been reported to influence telomerase activity, melatonin rhythms and antioxidant defenses. Its mechanism of action is not established.

Who it’s for, and who it isn’t

What’s included

• Online assessment and visit with a licensed clinician
• Review of personal and family cancer history and screening status
• Prescription only if appropriate and if a licensed pharmacy can lawfully dispense it
• Medication shipped from a licensed U.S. compounding pharmacy
• Follow-up to review goals and whether to continue
• No membership fee (labs priced separately)

Possible side effects

• Injection-site redness, itching or bruising
• Possible immune reactions; FDA staff flagged immunogenicity risk
• Systematic human side-effect data do not exist
• Long-term effects, including any effect on cancer risk, are unknown

This isn’t a complete list. Your clinician reviews risks, interactions and warnings with you before prescribing. In an emergency, call 911.

What the evidence says

A 2025 review in the International Journal of Molecular Sciences summarized about 25 years of research, mostly in cells, flies, rodents and other animals. Human data are limited to a few studies, including one in 162 people with retinitis pigmentosa and one in 75 women on circadian rhythm. The reviewers said key safety information is missing and called for toxicity, genotoxicity and carcinogenicity studies.

What epithalon is

Epithalon is a lab-made peptide of just four amino acids. It was designed to mirror the makeup of epithalamin, an extract of cattle pineal glands studied in Russia from the 1980s onward. You will also see it spelled epitalon or written as AEDG, after its amino acids.

It is promoted for healthy aging, sleep and 'telomere support.' Those uses come from early laboratory findings, not from completed clinical trials.

What the research shows

A 2025 review gathered roughly 25 years of epithalon research. Most of it was in cell cultures and animals including fruit flies, mice, rats and monkeys, plus computer modeling. The authors described antioxidant and neuroprotective effects in those settings.

Human research is scarce. The review identified a trial in 162 people with retinitis pigmentosa, an inherited eye disease, and a study of circadian rhythm in 75 women. Much of the published work comes from one research school, and independent, placebo-controlled trials in healthy midlife adults are lacking.

The same review stated that critical safety information is missing and that toxicity, genotoxicity and carcinogenicity studies are needed before it could be considered as a pharmaceutical ingredient.

The telomerase question

Telomeres are protective caps on the ends of chromosomes that shorten as cells divide. Telomerase is the enzyme that rebuilds them. Activating telomerase sounds like a route to younger cells, and that is the core of epithalon's appeal.

But telomerase has another side. The National Library of Medicine notes that telomerase is abnormally active in most cancer cells, which is part of how they keep dividing. Whether nudging telomerase in a healthy adult raises cancer risk has not been studied properly. That uncertainty is why we will not prescribe epithalon to anyone with active cancer and review any past cancer in detail.

Telomere length tests sold to consumers vary widely in method and are not a reliable way to judge whether epithalon is doing anything.

FDA status as of October 2026

Epithalon is not FDA-approved for any use. It was previously in Category 2 of the FDA's interim lists of bulk substances for compounding. In April 2026 its nomination was withdrawn, and the FDA moved it to its nominated-but-withdrawn list; that was not a safety finding and did not place it in Category 1.

On July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee considered epitalon for insomnia and voted 7 in favor of recommending it for the 503A bulks list, against the advice of FDA staff. Staff had noted no published efficacy studies in insomnia, a risk of immune reactions and possible impurities. The vote is advisory, and the FDA must still complete rulemaking, which had not happened as of October 2026.

HealifyMD only arranges a prescription when a licensed pharmacy confirms it can lawfully dispense the product under current federal and state rules.

Where it fits in a longevity plan

The measures with the strongest evidence for healthy aging are not peptides: regular strength and aerobic exercise, sleep, blood pressure and cholesterol control, not smoking, and recommended screenings. Your clinician will look at these first, often with baseline labs.

If you still want to try epithalon after that discussion, it is framed as a short, monitored experiment with a clear goal, not a long-term commitment.

Before starting, you and your clinician agree on what you hope to notice, such as sleep quality or energy, and when you will review it. If nothing meaningful changes by then, stopping is the expected outcome rather than a failure. Any new symptom, especially anything that could signal a cancer such as a lump, bleeding or unexplained weight loss, should be reported promptly.

Compounded, not FDA-approved

Epithalon from HealifyMD is a compounded preparation made by a licensed U.S. pharmacy for one patient. Compounded medicines are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality. Your clinician sets dosing and duration.

The price starts at $320/month, or $550 for two months ($275/month), with no membership fee, confirmed during your eligibility review. Labs are priced separately.

Go deeper on Epithalon (Epitalon)